Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry

被引:22
作者
Zhu, Kaixuan [1 ]
Xu, Yingying [2 ]
Fu, Jiaxin [1 ]
Mohamud, Farah Abdidahir [1 ]
Duan, Zongkui [1 ]
Tan, Siyuan [1 ]
Zhao, Zekun [3 ]
Chen, Ping [1 ]
Zong, Liang [1 ]
机构
[1] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Coll, Dept Gen Surg, Yangzhou, Jiangsu, Peoples R China
[2] Yangzhou Univ, Yizheng Peoples Hosp, Clin Med Coll, Dept Gen Surg, Yangzhou, Jiangsu, Peoples R China
[3] Tongji Univ, Med Sch, Tongji Hosp, Dept Gen Surg, Shanghai, Peoples R China
关键词
GASTROESOPHAGEAL JUNCTION; GASTRIC CARDIA; CANCER; EPIDEMIOLOGY; ESOPHAGUS; ESOPHAGECTOMY; SURVEILLANCE;
D O I
10.1155/2019/9637972
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background. To determine the ideal surgical approach (total gastrectomy (TG) vs. proximal gastrectomy (PG)) for Siewert type II adenocarcinoma of the esophagogastric junction (AEG), we searched and analyzed the Surveillance, Epidemiology, and End Results (SEER) data. Methods. Patients with Siewert type II AEG treated by TG or PG were identified from the 2004-2014 SEER dataset. We obtained the patients' overall survival (OS) and cancer-specific survival (CSS) and stratified the patients by surgical approach. We performed a propensity score 1 : 1 matching (PSM) analysis and a univariate and multivariate Cox proportional hazards model. Results. A total of 2,217 patients with 6th AJCC stage IA-IIIB Siewert type II AEG was examined: 1,584 patients (71.4%) underwent PG, and 633 patients (28.6%) underwent TG. The follow-up time was 1-131 months. OS favored total gastrectomy before the PSM analysis (chi 2=3.952, p=0.047), but after this analysis, there was no significant difference between TG and PG (chi 2=2.227, p=0.136). The univariate and multivariate analyses identified age as an independent factor, and an X-tail analysis revealed 70 years as a cut-off point. The patients aged >= 70 years obtained a significant long-term OS benefit from PG compared to TG (chi 2=8.245, p=0.004), and those aged<70 years showed no difference between TG and PG (chi 2=0.167, p=0.682). Conclusions. PG showed an equivalent survival benefit to TG in both the early and locally advanced stages of Siewert type II AEG. For elderly patients, PG is strongly recommended because of its clearer OS benefit compared to TG.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction
    Xiao, Jiang-Wei
    Liu, Zi-Lin
    Ye, Peng-Cheng
    Luo, Ya-Jun
    Fu, Zhi-Ming
    Zou, Qin
    Wei, Shou-Jiang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (34) : 9999 - 10007
  • [42] Short-Term and Long-Term Outcomes Following Transhiatal versus Right Thoracoabdominal Resection of Siewert Type II Adenocarcinoma of the Esophagogastric Junction
    Xing, Jiadi
    Liu, Maoxing
    Xu, Kai
    Gao, Pin
    Tan, Fei
    Yao, Zhendan
    Zhang, Nan
    Yang, Hong
    Zhang, Chenghai
    Cui, Ming
    Su, Xiangqian
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 11813 - 11821
  • [43] Safety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study)
    Omori, Takeshi
    Hara, Hisashi
    Shinno, Naoki
    Yamamoto, Masaaki
    Kanemura, Takashi
    Takeoka, Tomohira
    Akita, Hirofumi
    Wada, Hiroshi
    Yasui, Masayoshi
    Matsuda, Chu
    Nishimura, Junichi
    Ohue, Masayuki
    Sakon, Masato
    Miyata, Hiroshi
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (08) : 3387 - 3396
  • [44] Comparison of Efficacy Between Transabdominal and Transthoracic Surgical Approaches for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta-Analysis
    Li, Zonglin
    Jiang, Huaiwu
    Chen, Jin
    Jiang, Yifan
    Liu, Yi
    Xu, Linxia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Proximal gastrectomy versus total gastrectomy for proximal gastric carcinoma A meta-analysis on postoperative complications, 5-year survival, and recurrence rate
    Pu, Yu-Wei
    Gong, Wei
    Wu, Yong-You
    Chen, Qiang
    He, Teng-Fei
    Xing, Chun-Gen
    SAUDI MEDICAL JOURNAL, 2013, 34 (12) : 1223 - 1228
  • [46] Computed tomography-based nomogram of Siewert type II/III adenocarcinoma of esophagogastric junction to predict response to docetaxel, oxaliplatin and S-1
    Zhou, Chuan-Qinyuan
    Gao, Dan
    Gui, Yan
    Li, Ning-Pu
    Guo, Wen-Wen
    Zhou, Hai-Ying
    Li, Rui
    Chen, Jing
    Zhang, Xiao-Ming
    Chen, Tian-Wu
    WORLD JOURNAL OF RADIOLOGY, 2024, 16 (01):
  • [47] The development and validation of automated machine learning models for predicting lymph node metastasis in Siewert type II T1 adenocarcinoma of the esophagogastric junction
    Lu, Chenghao
    Liu, Lu
    Yin, Minyue
    Lin, Jiaxi
    Zhu, Shiqi
    Gao, Jingwen
    Qu, Shuting
    Xu, Guoting
    Liu, Lihe
    Zhu, Jinzhou
    Xu, Chunfang
    FRONTIERS IN MEDICINE, 2024, 11
  • [48] Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis
    Zhou, Yuan
    Tian, MengXiang
    Guengoer, Cenap
    Wang, Dan
    PLOS ONE, 2021, 16 (05):
  • [49] The Long-Term Outcomes of Surgery Versus Endoscopic Treatment in Patients With Siewert Type II T1M0N0 Adenocarcinoma of the Esophagogastric Junction
    Chen, Han
    Yu, Xin
    Yang, Ruoyun
    Li, Shuo
    Zhang, Guoxin
    Si, Xinmin
    Zhou, Xiaoying
    CANCER CONTROL, 2022, 29
  • [50] The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II
    Leers, Jessica M.
    Knepper, Laura
    van der Veen, Arjen
    Schroeder, Wolfgang
    Fuchs, Hans
    Schiller, Petra
    Hellmich, Martin
    Zettelmeyer, Ulrike
    Brosens, Lodewijk A. A.
    Quaas, Alexander
    Ruurda, Jelle P.
    van Hillegersberg, Richard
    Bruns, Christiane J.
    BMC CANCER, 2020, 20 (01)